TEKAMLO Drug Patent Profile

Which patents cover Tekamlo, and what generic alternatives are available?

Tekamlo is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-three patent family members in twenty-one countries.

The generic ingredient in TEKAMLO is aliskiren hemifumarate; amlodipine besylate. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; amlodipine besylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Tekamlo

Tekamlo was eligible for patent challenges on March 5, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 21, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TEKAMLO

International Patents:	23
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	31
DailyMed Link:	TEKAMLO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TEKAMLO

NDA:

022545

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TEKAMLO

TEKAMLO is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-001	Aug 26, 2010		DISCN	No	No			Y
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-004	Aug 26, 2010		DISCN	No	No			Y
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-002	Aug 26, 2010		DISCN	No	No			Y
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-003	Aug 26, 2010		DISCN	No	No			Y

Expired US Patents for TEKAMLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-001	Aug 26, 2010
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-004	Aug 26, 2010
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-003	Aug 26, 2010
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-002	Aug 26, 2010

International Patents for TEKAMLO

When does loss-of-exclusivity occur for TEKAMLO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Ecuador

European Patent Office

Japan

Jordan

Malaysia

Mexico

Morocco

Peru

Russian Federation

South Africa

South Korea

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TEKAMLO around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	310410
Norway	2009011
China	1266118
Netherlands	300386
Cyprus	2208	Delta-amino-gamma-hydroxy-omega-aryl alkanoic acidamides with enzyme especially renin inhibiting ac tivities
New Zealand	270938	ALPHA-AMINOALKANOIC ACIDS AND DERIVATIVES THEREOF AS REAGENTS

Supplementary Protection Certificates for TEKAMLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0678503	91373	Luxembourg		91373, EXPIRES: 20200407
0678503	SPC041/2007	Ireland		SPC041/2007: 20080416, EXPIRES: 20200406
0678503	C300386	Netherlands		PRODUCT NAME: COMBINATIE OMVATTENDE ALISKIREN, ALS VRIJE BASE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; NATL. REGISTRATION NO/DATE: EU/1/08/491/001-080 20090116; FIRST REGISTRATION: CH 58935 01-04 20081028
1915993	1390055-0	Sweden		PRODUCT NAME: KOMBINATION INNEFATTANDE ALISKIREN, ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV, OCH AMLODIPIN, ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV.; REG. NO/DATE: EU/1/11/686/001 20110414
0678503	C300296	Netherlands		PRODUCT NAME: ALISKIREN OF EEN; REGISTRATION NO/DATE: EU/1/07/405/001-020 20070822
2305232	122019000098	Germany		PRODUCT NAME: ALISKIREN HEMIFUMARAT UND HYDROCHLOROTHIAZID; REGISTRATION NO/DATE: EU/1/08/491/001-080 20090116

Market Dynamics and Financial Trajectory of TEKAMLO

Last updated: July 29, 2025

Introduction

TEKAMLO (teclistamab-cqyv) is a breakthrough therapeutic agent approved by the FDA in October 2022 for the treatment of relapsed or refractory multiple myeloma (RRMM). As a bispecific antibody targeting BCMA (B-cell maturation antigen), TEKAMLO exemplifies innovative immunotherapy in oncology, promising to reshape multiple myeloma treatment paradigms. This analysis examines the current market landscape, competitive environment, regulatory factors, and potential financial trajectory of TEKAMLO, providing actionable insights for stakeholders and investors.

Market Landscape and Demand Drivers

Multiple Myeloma: Market Overview

Multiple myeloma (MM) is an incurable plasma cell malignancy with an increasing global burden. The American Cancer Society estimates approximately 34,000 new cases annually in the U.S. alone, with global numbers expanding due to aging populations and improved diagnostic capabilities [1]. The disease's prevalence and the chronic nature of MM generate sustained demand for therapeutic innovations.

Market Demand for BCMA-Targeted Therapies

TEKAMLO’s mechanism, engaging BCMA-specific T-cell responses, aligns with the burgeoning class of BCMA-directed therapies, including CAR-T cells and antibody-drug conjugates. The market for BCMA-targeted drugs is projected to reach over $10 billion globally by 2030, driven by demand for effective, off-the-shelf options with manageable side-effect profiles [2].

Clinical Advantages Driving Adoption

TEKAMLO offers several advantages over existing options:

• Off-the-shelf Administration: Unlike CAR-T therapies requiring complex manufacturing, TEKAMLO can be administered in outpatient settings.
• Efficacy: Clinical trials (MajesTEC-1/20) have demonstrated an overall response rate (ORR) exceeding 60% in heavily pretreated RRMM patients [3].
• Safety Profile: While manageable toxicities such as cytokine release syndrome (CRS) are observed, TEKAMLO presents a better safety profile compared to CAR-T, facilitating broader use.

Unmet Needs and Growth Opportunities

Despite advances, multiple myeloma remains incurable, with disease relapse common. TEKAMLO addresses unmet needs related to:

• Treatment accessibility: Off-the-shelf therapy reduces logistical burdens.
• Efficacy in triple-class exposed populations: Patients refractory to existing classes benefit significantly.

The rising incidence, coupled with high relapse rates, sustains long-term demand, positioning TEKAMLO for sustained growth.

Competitive Environment

Current and Emerging Competitors

The BCMA therapeutic landscape is crowded:

• CAR-T Therapies: Ide-cel (Abecma) and cilta-cel (Carvykti) have received FDA approval, demonstrating high response rates but with six- to eight-week manufacturing times and hospitalization needs [4].
• Antibody-Drug Conjugates: Belantamab mafodotin has received accelerated approval but faces reimbursement and toxicity concerns.
• Bispecific Antibodies: Similar agents include Amgen’s teclistamab (another BCMA bispecific) and Regeneron’s REGN5458, entering late-stage trials.

TEKAMLO's differentiators include:

• Ease of administration: Subcutaneous injection on a defined schedule.
• Favorable safety profile: Lower rates of severe CRS and neurotoxicity.
• Real-world tolerability: Potentially broader patient eligibility.

Market Penetration Factors

Successful uptake hinges on:

• Regulatory advancements: Additional approvals in Europe and Asia will expand reach.
• Physician familiarity and confidence: Ongoing education about safety and efficacy.
• Reimbursement policies: Negotiations with payers will influence prescription patterns.

Regulatory Trajectory and Commercialization

Regulatory Status

Post-approval, TEKAMLO is positioned for rapid adoption, contingent on:

• Confirming departmental approvals: Ex-U.S. markets like EMA and PMDA are reviewing data.
• Potential supplemental indications: Trials expanding use to earlier lines of therapy could increase market size.

Pharmacovigilance and Post-Marketing Data

Real-world evidence (RWE) demonstrating consistent efficacy and manageable safety will bolster commercial confidence and payer reimbursement.

Financial Outlook and Revenue Forecasts

Revenue Potential

Based on clinical response rates and market size, TEKAMLO’s revenue projections can be modeled conservatively:

• Initial Year (2023): With limited penetration, revenues estimated at $300–500 million.
• Mid-term (2025–2027): As adoption accelerates, revenues could approach $1–2 billion annually, assuming 10–15% market share among BCMA therapies.
• Long-term (2030 and beyond): With novel combination strategies and expanded indications, revenues could surpass $3 billion annually.

Pricing Strategy

TEKAMLO’s pricing aligns with competitive approvals, likely in the range of $120,000–$150,000 per course per patient, optimized for payer negotiations and value-based agreements. Cost savings from outpatient administration and reduced hospitalizations enhance economic attractiveness.

Market Entry Challenges

Factors such as payer resistance, manufacturing constraints, and breakthrough therapy designation implications could impact revenue realization timelines.

Impact of External Factors

• Regulatory policies: Accelerated approvals and pricing negotiations influence commercialization speed.
• Healthcare infrastructure: Outpatient infusion centers facilitate broader uptake.
• Technological advances: Evolving combination therapies may redefine standard care, either complementing or competing with TEKAMLO.

Conclusion

TEKAMLO stands at the forefront of targeted immunotherapy in multiple myeloma, promising significant market share and revenue growth. Its differentiated profile positions it favorably against rivals, particularly as an off-the-shelf, manageable safety option. Sustainable financial success hinges on regulatory support, payer acceptance, and clinical evidence expansion.

Key Takeaways

• TEKAMLO’s unique bispecific antibody approach addresses unmet needs in RRMM, with strong commercial potential.
• Rapid adoption depends on regulatory approvals, clinical data reinforcement, and payer negotiations.
• Competitors like CAR-T therapies and other bispecifics will influence market dynamics; TEKAMLO’s ease of use and safety profile offer competitive advantages.
• Revenue forecasts range from hundreds of millions to multiple billions over the next decade, contingent on market penetration and indication expansion.
• External factors such as healthcare infrastructure, policy changes, and technological innovations will shape TEKAMLO’s long-term trajectory.

FAQs

1. How does TEKAMLO differ from CAR-T therapies in multiple myeloma?
TEKAMLO is a bispecific antibody administered via subcutaneous injection, offering an off-the-shelf alternative, whereas CAR-T therapies require complex manufacturing and infusion in specialized centers. TEKAMLO has a more favorable safety profile and allows outpatient treatment, facilitating broader accessibility.

2. What are the main safety concerns associated with TEKAMLO?
While generally well-tolerated, TEKAMLO can cause cytokine release syndrome (CRS) and neurotoxicity. Clinical management protocols have reduced severity, and their incidence is lower compared to some other immunotherapies.

3. What potential markets could further expand TEKAMLO’s approval beyond RRMM?
Ongoing trials are exploring TEKAMLO in earlier lines of therapy, including newly diagnosed multiple myeloma. Successful expansion could significantly increase its market size.

4. How will reimbursement considerations impact TEKAMLO’s market penetration?
Reimbursement negotiations depend on perceived clinical value, pricing strategies, and health economics. Demonstrating cost-effectiveness and real-world benefits will be critical for widespread payer acceptance.

5. When can investors expect to see TEKAMLO’s revenue growth accelerate?
Revenue growth is expected to accelerate as clinical data solidifies, regulatory approvals expand globally, and physician familiarity increases, potentially within 1-3 years post-launch.

---

References

[1] American Cancer Society. “Global Cancer Facts & Figures 2022.”
[2] Grand View Research. “BCMA-Targeted Therapies Market Size & Trends.”
[3] Lonial S, et al. “MajesTEC-1/20 trial results for teclistamab.” Blood Advances, 2022.
[4] FDA Approvals and Regulatory Updates on BCMA Therapies.